Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, real-world study evaluating first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer

Next Previous
Trial Profile

A retrospective, real-world study evaluating first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ESCKEYP trial

Most Recent Events

  • 01 Jan 2023 Results assessing difference in response rates, PFS and OS between patients with and without brain metastases, published in the Cancer Immunology Immunotherapy
  • 01 Dec 2022 Results (n=681) assessing the impact of KRAS mutation on the efficiency of first-line pembrolizumab immunotherapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 ≥ 50 %, published in the Lung Cancer.
  • 01 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top